In this video, InMed CEO Eric A. Adams speaks with BTV about InMed’s focus on cannabinoid-based pharmaceutical products. Mr. Adams talks about the company’s proprietary biosynthesis platform with potential to manufacture pharmaceutical-grade, high-yield cannabinoids.
![](https://www.inmedpharma.com/wp-content/uploads/2024/08/InMed-Native-Article_Neuron-close-up-768x432.png)
Article in Fierce Biotech: The Evolving Alzheimer’s Disease Landscape
There have been major advances in Alzheimer’s disease research and development in the past two years alone. What are those breakthroughs and what’s in development